Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thyrocare TechnologiesNSE:THYROCARE +6.70%88 PEG Ratio is 13.86 as of Jul. 21, 2026, which is 197% above its 10-year median of 4.66. GuruFocus rates NSE:THYROCARE with a GF Score™ of 88/100 and a GF Value™ of ₹396.88 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 36 Medical Diagnostics & Research companies, Thyrocare Technologies ranks worse than 91.67% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Thyrocare Technologies's PEG Ratio or its related term are showing as below:
NSE:THYROCARE'
s PEG Ratio Range Over the Past 10 Years
Min: 1.63 Med: 4.66 Max: 197.46
Current: 13.86
During the past 13 years, Thyrocare Technologies's highest PEG Ratio was 197.46. The lowest was 1.63. And the median was 4.66.
NSE:THYROCARE's PEG Ratio is ranked worse than 91.67% of 36
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.405
vs NSE:THYROCARE: 13.86
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Thyrocare Technologies (NSE:THYROCARE) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: PEG Ratio Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Thyrocare Technologies (NSE:THYROCARE) has a PEG Ratio of 13.86 as of Jul. 21, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Thyrocare Technologies and its competitors. This is 197% above median its historical median of 4.66. Over the past decade, Thyrocare Technologies' PEG Ratio has ranged from 1.63 to 197.46. According to the industry distribution chart, Thyrocare Technologies ranks #33 out of 36 companies in the Medical Diagnostics & Research industry, placing it in the top 91.7%.
Is Thyrocare Technologies' PEG Ratio too high?
Thyrocare Technologies' current PEG Ratio of 13.86 is 197% above median its 10-year median of 4.66. Over the past 10 years, this metric has ranged from a low of 1.63 to a high of 197.46. The Medical Diagnostics & Research industry median PEG Ratio is 2.41. Thyrocare Technologies' value of 13.86 is 476.3% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #33 out of 36 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #33 out of 36 companies for PEG Ratio. This places Thyrocare Technologies in the lower half of its industry. The industry median PEG Ratio is 2.41. Thyrocare Technologies' value of 13.86 is 476.3% above this benchmark. Historically, Thyrocare Technologies' own PEG Ratio has ranged from 1.63 to 197.46 over the past decade. While the company's 10-year median is 4.66 vs. the industry median of 2.41, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.41, based on 36 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current PEG Ratio of 13.86 is 476.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current PEG Ratio is 13.86, which is 197% above median its own 10-year median of 4.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹396.88, compared to a current price of ₹555.50 — trading 40% above its estimated fair value. The current PEG Ratio is 13.86, which is 197% above median its 10-year median of 4.66 and 476.3% above the Medical Diagnostics & Research industry median of 2.41. Thyrocare Technologies' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current PEG Ratio is 13.86 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹555.50 is trading 40% above its estimated GF Value™ of ₹396.88.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
PEG Ratio: 13.86 (197% above median its 10-year median of 4.66)
GF Value™: ₹396.88 vs. price of ₹555.50 (40% above fair value)
Industry Position: 476.3% above the Medical Diagnostics & Research median (#33 of 36)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
88GF Score
Get the complete analysis for NSE:THYROCARE
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
